Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients - ACR Meeting Abstracts
